Enanta製藥 ENTA 深 滬
已收盤 07-02 16:00:00 美东时间
15.11
+0.340
+2.30%
華盛通- 最 高15.51
- 今 開14.88
- 成交量 29.94万股
- 最 低 14.77
- 昨 收 14.77
- 總市值 43.94万
- 52周最高 17.15
- 市盈率 靜 --
- 換手率 1029.72%
- 52周最低 6.435
- 委 比 50.75%
- 總股本 2.91万
- 歷史最高 127.77
- 量 比 0.77
- 振 幅 5.01%
- 歷史最低 4.09
- 每 手 1
- 風險率 2.64%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Enanta Pharmaceuticals Establishes Flexible At-The-Market Offering
An update from Enanta Pharmaceuticals ( ($ENTA) ) is now available. On July 2, ...
07-03 05:18
Enanta Pharmaceuticals Enters Open Market Sale Agreement With Jefferies; May Offer And Sell Up To $75M Of Common Stock Through Jefferies
Enanta Pharmaceuticals Enters Open Market Sale Agreement With Jefferies; May Offer And Sell Up To $75M Of Common Stock Through Jefferies
07-03 04:58
美股大行评级 | 美银上调美光科技目标价从950美元升至1500美元，上调迈威尔科技目标价从240美元升至365美元
今日重点评级关注：摩根士丹利：维持杜邦"标配"评级，目标价从52美元升至156美元；蒙特利尔银行：维持Taysha Gene Therapies"跑赢大市"评级，目标价从10美元升至14美元
06-24 14:08
Enanta Faces Patent Setback in Paxlovid Litigation
The latest announcement is out from Enanta Pharmaceuticals ( ($ENTA) ). Enanta ...
06-24 06:43
AbbVie, Enanta announce EU label expansion for hepatitis C therapy, Maviret
AbbVie (ABBV) and Enanta Pharmaceuticals (ENTA) announced on Tuesday that the European Commission has approved a label expansion for their jointly developed hepatitis C therapy, Maviret. Accordingly, ...
06-23 19:34
EU approves AbbVie’s Mavyret, discovered by Enanta, for acute hepatitis C treatment
EU approves AbbVie’s Mavyret, discovered by Enanta, for acute hepatitis C treatment European Commission cleared AbbVie’s Maviret (glecaprevir/pibrentasvir) to treat acute hepatitis C in adults and children aged 3+ in the EU. The label expansion makes Maviret the only EU-approved therapy for both acu
06-23 17:10
Enanta Pharma Advances Zelicapavir Into Registrational Phase 2b/3 Clinical Trial In Adults At High Risk Of Severe Outcomes From RSV Infection After End-Of-Phase 2 Meeting With FDA
Registrational Ph2b/3 Trial of Zelicapavir to Initiate in High-Risk Adults with RSV in 4Q 2026, with Topline Phase 2b Data Expected in 2027 Phase 2b Trial of Zelicapavir to Initiate in Pediatric Patients with RSV in 3Q 2026, with Topline Data Expected in 2027 Enanta Pharmaceuticals, Inc. (NASDAQ:ENT...
06-18 19:06
Enanta将出席Jefferies全球医疗大会 聚焦RSV与免疫管线进展
Enanta Pharmaceuticals周四宣布，公司将出席即将举行的Jefferies全球医疗大会，与投资者分享其在呼吸道合胞病毒治疗和免疫学领域的最...
05-28 23:17
European Medicines Agency Announces Meeting highlights From The Committee For Medicinal Products for Human Use, May 18-21
https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-18-21-may-2026
05-22 18:59
Enanta Pharma shares are trading lower. The company reported Q2 financial results.
Enanta Pharma shares are trading lower. The company reported Q2 financial resul...
05-13 00:43
